PubRank

Franco Patrone

Author PubWeight™ 36.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004 1.82
2 Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005 1.53
3 Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 2004 1.44
4 Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorg Med Chem 2010 1.40
5 Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 2009 1.30
6 Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012 1.23
7 The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2007 1.18
8 Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 2006 1.14
9 The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem 2012 1.11
10 Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007 1.10
11 Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal 2012 1.04
12 Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 2005 1.03
13 Autophagy in blood cancers: biological role and therapeutic implications. Haematologica 2013 0.99
14 The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 2006 0.97
15 New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des 2013 0.95
16 Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res 2004 0.94
17 Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood 2013 0.93
18 Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 2010 0.92
19 Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 2011 0.90
20 Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leuk Lymphoma 2010 0.89
21 A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. Leuk Res 2010 0.89
22 Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol 2012 0.88
23 Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 2010 0.88
24 Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy 2013 0.87
25 Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS One 2010 0.85
26 APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood 2009 0.85
27 Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2013 0.84
28 Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability. Breast Cancer Res Treat 2003 0.82
29 Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther 2003 0.82
30 Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol 2011 0.81
31 Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leuk Lymphoma 2012 0.81
32 Doxorubicin-induced expression of LOX-1 in H9c2 cardiac muscle cells and its role in apoptosis. Biochem Biophys Res Commun 2005 0.81
33 New insights into biology of chronic myeloid leukemia: implications in therapy. Curr Cancer Drug Targets 2013 0.78
34 Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. Curr Cancer Drug Targets 2013 0.78
35 Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2007 0.77
36 Parameter space exploration within dynamic simulations of signaling networks. Math Biosci Eng 2013 0.76
37 Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. Bioorg Med Chem 2011 0.76
38 Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma. Eur J Haematol 2002 0.75
39 Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes. Tumori 2014 0.75
40 Chronic myeloid leukemia: reaching for the cure. Curr Cancer Drug Targets 2013 0.75